Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ep 144: ESC 25 in Review with Dr Purvi Parwani
Added: 6 months ago
In this evidence-packed episode of Parallax, Dr Ankur Kalra welcomes back Dr Purvi Parwani, Associate Professor of Medicine at Loma Linda University Health, for a comprehensive review of groundbreaking trials presented at the European Society of Cardiology Congress.Dr Parwani guides listeners through what she describes as a "tectonic shift" in post-MI care with the REBOOT and BETAMI-DANBLOCK… View more

Guidelines & Statements

Heart Failure
Late-Breaking Sessions Revealed for HSFA Annual Scientific Meeting 2025
Added: 7 months ago Source:  HFSA 2025 Scientific Programme
HSFA Annual Scientific Meeting 2025 has released its late-breaking clinical research sessions which are to be presented in September 2025.The meeting is set to take place from the 26th to 29th September 2025 at Minneapolis Convention Center in Minnesota, US.Access the full programme here.Late Breaking Clinical Research 1: Devices and CardiomyopathiesSunday 28th September, 09:00am – 10:30am (CDT… View more

Vascular Disease and Surgery

Demographic
MicroRNAs for Cardiac Regeneration
Author(s): Camilla Olianti , Mauro Giacca Added: 6 months ago

Prevention & Chronic Conditions

Heart Failure
Ventricular Tachycardia After Cardioversion
Author(s): Eiad Habib , Mahmoud Abdelnabi , Ramzi Ibrahim , et al Added: 4 months ago

Electrophysiology & Arrhythmia

Heart Failure
AI Tool Accurately Detects Cardiac Amyloidosis on Echo
Added: 5 months ago Source:  Radcliffe Cardiology
Differentiating cardiac amyloidosis (CA) from its phenotypic mimics remains a clinical challenge. A new study published in the European Heart Journal details the development and validation of a novel artificial intelligence (AI) model that can accurately screen for CA using only a single apical four-chamber echocardiogram video clip.¹This retrospective, multisite, multiethnic study first trained… View more

Imaging & Diagnostics

Demographic
AHA 2024 Late-Breaking and Featured Science Collection
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem andDr Joost Daemen (Thoraxcenter,… View more

Intervention

Prevention & Chronic Conditions
Mavacamten Fails to Meet Primary Endpoints in Non-obstructive Hypertrophic Cardiomyopathy
Added: 7 months ago Source:  Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England… View more

Guidelines & Statements

Heart Failure
Synchronisation Effects on Metabolism
Author(s): Pawut Gumrai , Wanwarang Wongcharoen , Siriporn C Chattipakorn , et al Added: 1 month ago

Intervention

Heart Failure
HFpEF-ABA Score Outperforms NT-proBNP in Trial Enrichment
Added: 4 months ago Source:  Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can… View more

Imaging & Diagnostics

Cardiovascular Renal Metabolic
Acoramidis Efficacy in ATTR-CM Genotypes
Added: 5 months ago Source:  Radcliffe Cardiology
New analyses from the ATTRibute-CM trial show that the transthyretin (TTR) stabiliser acoramidis provides consistent clinical benefits in patients with both wild-type (ATTRwt-CM) and variant (ATTRv-CM) transthyretin amyloid cardiomyopathy.1 The findings include data from the main 30-month trial and its ongoing 42-month open-label extension (OLE).Acoramidis is an orally administered, small… View more

Inherited and Congenital Cardiac Conditions

Heart Failure